 |
 |

Survival and Prognosis in Hürthle Cell Carcinoma of the Thyroid Gland
Neil Bhattacharyya, MD
Arch Otolaryngol Head Neck Surg. 2003;129:207-210.
Objective To determine factors that affect survival in patients with Hürthle cell carcinoma of the thyroid gland.
Methods Data for all cases of Hürthle cell carcinoma that occurred between January 1, 1988, and December 31, 1998, were extracted from the Surveillance, Epidemiology, and End Results database. Clinical data regarding age, sex, tumor size, primary site extension, nodal involvement, and vital status were tabulated. Patients with distant metastases were excluded, and Kaplan-Meier survival analysis was conducted. Survival data for patients with Hürthle cell carcinoma were compared with data for a control group of patients with follicular cell carcinoma matched for age, sex, tumor size, and local disease extension. Cox multivariate regression analysis was conducted to determine the effect of predictor variables on overall survival in Hürthle cell carcinoma.
Results We identified 555 cases of nonmetastatic Hürthle cell carcinoma (mean age at diagnosis, 55.9 years; women, 67.9%). The primary tumor was intrathyroidal in 83.8% of patients, whereas 11.2% had minor local extension. Mean tumor size was 3.5 cm. Mean, 5-year, and 10-year survival for Hürthle cell carcinoma was 109 months, 85.1%, and 71.1%, respectively. Mean survival for 411 matched patients with follicular cell carcinoma was 113 months, which was not statistically different from that of patients with Hürthle cell carcinoma (P = .47, log-rank test). On multivariate analysis, increasing age at diagnosis, male sex, and increasing tumor size were statistically significant predictors of poor survival; degree of primary site extension did not affect survival.
Conclusions Overall survival for Hürthle cell carcinoma is similar to that of comparably staged follicular cell carcinoma. Increasing age, male sex, and increasing tumor size substantially diminish survival in patients with Hürthle cell carcinoma.
From the Division of Otolaryngology, Brigham and Women's Hospital, and the Department of Otology and Laryngology, Harvard Medical School, Boston, Mass.
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Diagnostic Accuracy and Prognostic Value of 18F-FDG PET in Hurthle Cell Thyroid Cancer Patients
Pryma et al.
JNM 2006;47:1260-1266.
ABSTRACT
| FULL TEXT
Benign Hurthle Cell Adenoma with Papillary Architecture: A Benign Lesion Mimicking Oncocytic Papillary Carcinoma
Mai et al.
INT J SURG PATHOL 2005;13:37-41.
ABSTRACT
Surgical Treatment of Cervical Nodal Metastases in Patients With Papillary Thyroid Carcinoma
Bhattacharyya
Arch Otolaryngol Head Neck Surg 2003;129:1101-1104.
ABSTRACT
| FULL TEXT
Survival and Staging Characteristics for Non-Squamous Cell Malignancies of the Maxillary Sinus
Bhattacharyya
Arch Otolaryngol Head Neck Surg 2003;129:334-337.
ABSTRACT
| FULL TEXT
|